Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Nov 27, 2024; 16(11): 3463-3470
Published online Nov 27, 2024. doi: 10.4240/wjgs.v16.i11.3463
Published online Nov 27, 2024. doi: 10.4240/wjgs.v16.i11.3463
Clinical study of different interventional treatments for primary hepatocellular carcinoma based on propensity-score matching
Xiao-Bo Cheng, Li Yang, Yi-Bo Peng, Lei Wang, Shuang-Ming Zhu, Zhi-Wei Hu, Zhong-Liang Wang, Qin Yang, Department of Oncology, Dangyang People’s Hospital, Dangyang 444100, Hubei Province, China
Ming-Qian Lu, Department of Oncology, Yichang Central People’s Hospital (The First Clinical Medical School of China Three Gorges University), Yichang 443008, Hubei Province, China
Co-first authors: Xiao-Bo Cheng and Li Yang.
Author contributions: Cheng XB and Yang L contributed equally to this work. Cheng XB and Yang L designed the manuscript; Lu MQ supervised this study; Yang Q analyzed the data and supervised this study; Peng YB and Wang L prepared the figures; Zhu SM, Hu ZW, and Wang ZL organized the clinical data.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Dangyang People’s Hospital.
Informed consent statement: Informed consent was waived due to the retrospective nature of the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data used in this study can be obtained from the corresponding author upon request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qin Yang, MBBS, Chief Physician, Department of Oncology, Dangyang People’s Hospital, No. 71 Yuyang Road, Dangyang 444100, Hubei Province, China.
Received: August 8, 2024
Revised: September 9, 2024
Accepted: September 25, 2024
Published online: November 27, 2024
Processing time: 83 Days and 6.1 Hours
Revised: September 9, 2024
Accepted: September 25, 2024
Published online: November 27, 2024
Processing time: 83 Days and 6.1 Hours
Core Tip
Core Tip: Primary hepatocellular carcinoma is a malignant digestive disease with a high mortality rate. In this study, we found that drug-eluting bead transcatheter arterial chemoembolization treatment has more obvious effects than conventional transcatheter arterial chemo-embolization treatment. It can improve the liver function indices and tumor marker levels of these patients and does not increase the rate of liver toxicity or adverse reactions.